Juli is the Vice President of CMC and Product Development at IconOVir Bio. Prior to IconOVir she was Managing Director of the Life Science Consulting Group, L.L.C. supporting CMC due diligence, IND packages and GMP manufacturing strategies for clients including Dr. Clodagh O’Shea at the Salk Institute for Biological Studies. Juli joined the Department of Oncology at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland as Director and Qualified Person, where she was responsible for the planning and development of the Cell and Gene Therapy Clinical Manufacturing Facility. Prior to that, Juli held roles of increasing responsibility during a 25-year career with Johnson and Johnson. She was a bench scientist in the development of vaccines, therapeutic antibodies and cellular immunotherapies; as Associate Scientific Director she led the R&D effort in a proprietary autologous T-cell platform for the treatment of cancer; and as Head of Quality Control was responsible for test method development and product release.
Juli received her B.A. in Biochemistry and Cell Biology at the University of California at San Diego.